Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients: The RENAISSANCE Trial (RENAISSANCE)

16. november 2026 oppdatert av: Vikas Sridhar, University of British Columbia

Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients (RENAISSANCE): A Randomized, Placebo-controlled, Double Blinded, Multicenter Clinical Trial of Sotagliflozin Versus Placebo

This study will examine whether sotagliflozin, a medication that may protect the heart and kidneys, can improve long-term health in people who have received a kidney transplant. The study will compare sotagliflozin with an inactive placebo in approximately 900 adult kidney transplant recipients. Researchers will assess whether the medication can reduce the risk of kidney transplant failure, worsening kidney function, heart problems, stroke, heart attack, heart failure, and death. The study will also closely monitor participants for possible side effects, including infections, dehydration, fractures, and rejection of the transplanted kidney.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

RENAISSANCE (Cardiovascular and Renal Protection with SGLT Inhibition in Kidney Transplant Recipients) is a pragmatic, prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sotagliflozin in adult kidney transplant recipients (KTRs).

Scientific Background and Rationale

Kidney transplant recipients remain at substantial risk of premature death, cardiovascular disease (CVD), heart failure (HF), and progressive loss of kidney transplant function. Cardiovascular complications are a leading cause of death among KTRs, while progressive deterioration in allograft function remains a major contributor to long-term transplant failure. These cardiovascular and kidney complications are interrelated, with deterioration in either organ system potentially contributing to dysfunction in the other.

Sodium-glucose cotransporter (SGLT) inhibitors have demonstrated cardiovascular and kidney protective effects in individuals with diabetes, heart failure, and chronic kidney disease (CKD), including reductions in cardiovascular events, hospitalization for heart failure, and progression of kidney disease. However, kidney transplant recipients have largely been excluded from previous large randomized clinical trials because of concerns regarding infection, volume depletion, and potential effects on transplant function and rejection. Although small randomized studies and observational data in KTRs suggest potential benefits and an acceptable safety profile, adequately powered randomized evidence is lacking.

RENAISSANCE is designed to address this evidence gap by evaluating whether sotagliflozin can improve long-term cardiovascular and kidney outcomes in KTRs while maintaining an acceptable safety profile.

Study Design and Intervention

Approximately 900 adult kidney transplant recipients will be randomized in a 1:1 ratio to receive either sotagliflozin 200 mg orally once daily or matching placebo. Study treatment will be administered in addition to participants' usual kidney transplant care, including maintenance immunosuppressive therapy and individualized management of cardiovascular risk factors.

Randomization will be stratified according to diabetes status and time since transplantation (less than 5 years versus 5 years or longer). The study will be double-blinded, with participants, investigators, study coordinators, and clinical site personnel unaware of treatment assignment. Active treatment and placebo tablets will be identical in appearance. Treatment allocation will be accessible only to designated unblinded pharmacy and coordinating center personnel, with emergency unblinding available when medically necessary.

Participants will receive study intervention for up to approximately 4.5 years, depending on enrollment timing, and will remain in the study until study closeout. Study medication will be discontinued approximately 4 weeks before the end of the study to allow assessment of kidney function following treatment withdrawal.

Participant Follow-up and Study Procedures

RENAISSANCE incorporates a pragmatic study design intended to minimize participant burden and facilitate participation across geographically diverse populations. Study visits may be conducted in person, by telephone, or through secure video communication, according to participant and investigator preference. Participants are not required to travel to their transplant center for study visits or laboratory testing.

Following randomization and initiation of study medication, participants will have an initial safety assessment approximately 2 to 6 weeks after starting treatment. This assessment includes evaluation of serum creatinine and estimated glomerular filtration rate (eGFR) to monitor kidney function following treatment initiation.

Subsequent study assessments will occur approximately every 3 months, with a 28-day visit window. Assessments will include review of medical history, concomitant medications, study medication adherence, adverse events, weight, and blood pressure. Serum creatinine and other clinically available laboratory results will be collected approximately every 3 months, while urine albumin-to-creatinine ratio will be assessed approximately every 6 months.

Whenever possible, laboratory results and clinical measurements obtained as part of routine transplant care will be used for study purposes to minimize additional testing. Participants may use their local laboratory and healthcare providers, with appropriate authorization for collection of clinical information. If required laboratory assessments are not available through routine care, study-related testing will be arranged.

At the end of the treatment period, kidney function will be assessed at study medication discontinuation and again approximately 4 weeks after discontinuation to evaluate changes following the treatment washout period.

Safety Monitoring and Risk Mitigation

The safety of sotagliflozin in kidney transplant recipients is a central component of the study. Particular attention will be given to potential adverse effects associated with SGLT inhibition, including genital mycotic infections, urinary tract infections, volume depletion, symptomatic hypotension, diabetic ketoacidosis, hypoglycemia, diarrhea, bone fractures, and changes in kidney function. The study will also monitor for acute kidney injury, infections requiring emergency care or hospitalization, kidney biopsy, and biopsy-proven acute transplant rejection.

Participants will receive counseling regarding potential risks and appropriate precautions during treatment. They will be instructed to temporarily hold study medication during periods of acute illness or fasting and during treatment of intercurrent urinary tract or genital yeast infections, in consultation with their healthcare provider and study investigator. Investigators may also coordinate adjustments to concomitant diuretics or glucose-lowering medications when clinically indicated to minimize the risk of volume depletion or hypoglycemia.

Study medication may be permanently discontinued when continued treatment is considered inappropriate for participant safety, including clinically significant adverse events, initiation of dialysis, kidney retransplantation, or pregnancy. Discontinuation of study medication does not automatically result in withdrawal from the study. Participants will be encouraged to continue study follow-up, allowing collection of clinical outcomes and safety information regardless of treatment discontinuation.

Outcome Assessment and Analysis

The study will evaluate the effects of sotagliflozin on major cardiovascular and kidney outcomes, including mortality, kidney transplant failure, cardiovascular events, heart failure events, and changes in kidney function over time. Clinical events, including cause of death, stroke, myocardial infarction, and heart failure events, will be reviewed by an independent adjudication committee blinded to treatment assignment.

The primary efficacy analysis will use a hierarchical composite approach that prioritizes clinically important outcomes, with all-cause mortality and kidney transplant loss ranked above cardiovascular events, sustained decline in kidney function, and heart failure events. Longitudinal kidney function will also be evaluated using eGFR trajectories over the treatment period. Additional analyses will assess cardiovascular and kidney outcomes, metabolic measures, albuminuria, and safety events.

The study will compare outcomes between the sotagliflozin and placebo groups to determine whether treatment provides cardiovascular and kidney protection without an unacceptable increase in adverse events.

Studietype

Intervensjonell

Registrering (Antatt)

900

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • New South Wales
    • South Australia
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2B7
        • University of Alberta
        • Ta kontakt med:
          • Sita Gourishankar, MD, FRCPC, SM (Epid)
          • Telefonnummer: 780-492-2532
          • E-post: sitag@ualberta.ca
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 1Y6
        • St. Paul's Hospital
        • Ta kontakt med:
      • Vancouver, British Columbia, Canada
        • Vancouver General Hospital
        • Ta kontakt med:
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • Queen Elizabeth II Health Sciences Centre
        • Ta kontakt med:
    • Ontario
      • Hamilton, Ontario, Canada, L8N 4A6
        • St. Joseph's Healthcare Hamilton
        • Ta kontakt med:
      • Kingston, Ontario, Canada, K7L2V7
        • Kingston General Hospital
        • Ta kontakt med:
          • M. Khaled Shamseddin, MD MSc
          • Telefonnummer: 613-766-0654
          • E-post: ks136@queensu.ca
      • London, Ontario, Canada, N6A 5A5
      • Ottawa, Ontario, Canada, K1H 8L6
        • The Ottawa Hospital
        • Ta kontakt med:
          • Gregory Knoll, MD MSc
          • Telefonnummer: 613-737-8755
          • E-post: gknoll@toh.ca
      • Toronto, Ontario, Canada, M5C 2T2
        • St. Michael's Hospital
        • Ta kontakt med:
      • Toronto, Ontario, Canada, M5G 2N2
        • University Health Network
        • Ta kontakt med:
    • Quebec
      • Montreal, Quebec, Canada, H4A 0B1
        • McGill University Health Centre
        • Ta kontakt med:
      • Montreal, Quebec, Canada, H2X 0A9
      • Québec, Quebec, Canada, G1V 0E8
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7M 0Z9
        • St. Paul's Hospital
        • Ta kontakt med:
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • University of Minnesota
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10065
        • NewYork-Presbyterian / Weill Cornell Medical Center
        • Ta kontakt med:
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27514
        • UNC Medical Center
        • Ta kontakt med:
      • Auckland, New Zealand
      • Barcelona, Spania, 08003
        • Hospital del Mar
        • Ta kontakt med:
          • Marta Crespo, MD PhD
          • Telefonnummer: 8667 +34-93-254-34-50
          • E-post: mcrespo@hmar.cat
      • Birmingham, Storbritannia
        • University Hospitals Birmingham
        • Ta kontakt med:
      • London, Storbritannia, NW3 2QG
        • Royal Free Hospital
        • Ta kontakt med:
      • London, Storbritannia, SW17 0QT
      • Berlin, Tyskland, 10117
        • Charité Universitätsmedizin Berlin
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥ 18 years

  2. ≥ 6 months post living or deceased donor kidney transplant

  3. Estimated glomerular filtration rate (eGFR) ≥20 ml/min/1.73m2 by the CKD-EPI-creatinine 2021 formula within 28 days prior to randomization.

  4. At increased risk for worsening allograft function or cardiovascular event as defined by one of the following groups:

    1. Type 2 diabetes
    2. Body mass index ≥ 30 kg/m2
    3. History of post-kidney transplant hospitalization for congestive heart failure (regardless of ejection fraction)
    4. eGFR <30 ml/min/1.73m2
    5. Albuminuria (UACR ≥ 11.3 mg/mmol or urine protein to creatinine ratio (UPCR) ≥ 500 mg/g) within 28 days of randomization and a second urine sample over the prior two years; the rationale for this cut-point is that given the patient-centered study design, we are not necessitating first morning voids and random urine specimen albumins are usually higher than first morning samples.
    6. History of CV event (myocardial infarction, stroke)
    7. At risk for CV event (history of coronary artery bypass, percutaneous coronary intervention, peripheral artery bypass or stent, or age ≥50yr (men) or ≥60yr (women) with at least two additional risk factors: hypertension, hyperlipidemia or current smoker (see MOP for definitions of hypertension and hyperlipidemia).
  5. Ability of the participant or Legally Authorized Representative to understand and sign a written informed consent.

  6. Ability to comply with all components of the study

Exclusion Criteria:

  1. SGLT inhibitor use in the previous 3 months

  2. Type 1 diabetes

  3. Multi-organ or extrarenal transplant (except cornea)

  4. Acute coronary syndrome, transient ischemic attack or stroke within 1 month prior to screening

  5. Suspicion for acute rejection and/or plans for kidney biopsy

  6. Acute rejection within 3 months prior to screening

  7. Ongoing treatment for rejection

  8. Acute kidney injury (AKI) in the last 3 months (may be rescreened)

  9. History of diabetic ketoacidosis in the last 5 years

  10. High risk for urinary tract infection (UTI) (e.g. need for indwelling or recurrent catheterization, or frequent (>3 per year) UTIs)

  11. Active treatment for BK nephropathy, Cytomegalovirus viremia, Epstein Barr Virus viremia

  12. Active immunosuppressive treatment for recurrent/post-transplant glomerulonephritis

  13. Severe hepatic impairment (Child-Pugh class C)

  14. Current treatment with rifampicin

  15. Pregnancy, lactation or women of child-bearing potential* unless taking adequate precautions to avoid the possibility of becoming pregnant (as defined in the manual of procedures) until 4 weeks after the last dose of study drug

  16. Known allergic reactions to components of sotagliflozin

  17. Current treatment with another investigational drug or device

  18. Incarcerated individuals

  19. History of any other acute or chronic medical condition (e.g., urogenital abnormalities) or pre-planned surgical procedure that in the opinion of the investigator would compromise the safety of the patient or the integrity of the study results.

    • A woman of child-bearing potential is defined as a participant who has:

      • Experienced menarche and engages in activity that involves penile-vaginal intercourse with a partner capable of causing pregnancy AND
      • Has not undergone surgical sterilization (hysterectomy, bilateral salpingectomy/oophorectomy) or is not postmenopausal (≥12 consecutive months of spontaneous amenorrhea without an alternative medical cause).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Matching placebo will be administered for 3-4.5 years.

Eksperimentell: Sotagliflozin

Sotagliflozin 200 mg PO OD will be administered for 3-4.5 years.

Andre navn:
  • LX4211

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hierarchical Composite of All-Cause Mortality, Kidney Transplant Loss, Non-Fatal Stroke or Myocardial Infarction, Sustained 40% Decline in eGFR, Heart Failure Events, and Total eGFR Slope
Tidsramme: From randomization to the end of the study (up to 4.5 years), with eGFR slope assessed from screening to the last on-study drug visit.

A hierarchical composite endpoint consisting of the following components, ranked in order of clinical importance:

  1. All-cause mortality.
  2. Kidney transplant loss, defined as chronic dialysis for more than 90 days, retransplantation, or sustained eGFR ≤15 mL/min/1.73 m² for more than 3 months.
  3. Non-fatal stroke or non-fatal myocardial infarction (MI).
  4. Sustained 40% decline in estimated glomerular filtration rate (eGFR) from screening, confirmed by two creatinine measurements obtained at least 3 months apart.
  5. Heart failure (HF) events, defined as hospitalization for HF or urgent treatment for HF.
  6. Total eGFR slope, calculated using longitudinal eGFR measurements from screening to the last on-study drug visit and expressed in mL/min/1.73 m²/year.

The hierarchical composite will compare treatment groups according to the prespecified ranking of these outcomes.

From randomization to the end of the study (up to 4.5 years), with eGFR slope assessed from screening to the last on-study drug visit.
Number of Participants Experiencing Serious Adverse Events
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants experiencing one or more serious adverse events (SAEs) during the study. Serious adverse events will be defined according to the applicable regulatory criteria for seriousness.

From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Adverse Events Leading to Permanent Study Drug Discontinuation
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants who permanently discontinue the assigned study drug due to an adverse event.

From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Study Drug-Related Adverse Events
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants experiencing at least one adverse event considered related to the study drug by the investigator.

From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Adverse Events of Special Interest
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants experiencing at least one adverse event of special interest (AESI) during the study period. Adverse events of special interest include:

  • Genital mycotic infections
  • Urinary tract infections
  • Infectious complications requiring an emergency department visit or hospitalization
  • Amputations
  • Bone fractures
  • Diabetic ketoacidosis
  • Symptomatic hypotension
  • Symptomatic hypoglycemic episodes
  • Diarrhea
  • Kidney biopsy
  • Biopsy-proven acute rejection

Each adverse event will be assessed and recorded throughout the study. Participants experiencing one or more adverse events of special interest will be counted in this outcome measure.

From randomization to the end of the study (up to 4.5 years).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants Experiencing All-Cause Mortality
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants who die from any cause during the study period.

From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Kidney Transplant Loss
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants experiencing kidney transplant loss, defined as any of the following:

  • Requirement for chronic dialysis for more than 90 days.
  • Kidney retransplantation.
  • Sustained eGFR ≤15 mL/min/1.73 m² for more than 3 months.
From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Non-Fatal Stroke or Non-Fatal Myocardial Infarction
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants experiencing a non-fatal stroke or non-fatal myocardial infarction during the study period.

From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing a Sustained 40% Decline in eGFR
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants experiencing a sustained decline of 40% or greater in estimated glomerular filtration rate (eGFR) from screening. The decline must be confirmed by two serum creatinine measurements obtained at least 3 months apart.

From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Heart Failure Hospitalization or Urgent Heart Failure Treatment
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants experiencing a heart failure event, defined as hospitalization for heart failure or urgent treatment for heart failure.

From randomization to the end of the study (up to 4.5 years).
Total eGFR Slope from Screening to the End of Study Drug Treatment
Tidsramme: From randomization to the end of the study (up to 4.5 years).

The total eGFR slope represents the rate of change in estimated glomerular filtration rate (eGFR), expressed in mL/min/1.73 m²/year. It will be calculated using longitudinal eGFR measurements obtained from screening to the end of study drug treatment.

From randomization to the end of the study (up to 4.5 years).
Hierarchical Composite of Kidney Death, Kidney Transplant Loss, Sustained 40% Decline in eGFR, and Total eGFR Slope
Tidsramme: From randomization to the end of the study (up to 4.5 years); eGFR slope assessed from screening to the end of study drug treatment.

A hierarchical composite kidney endpoint consisting of the following components:

  1. Kidney death.
  2. Chronic dialysis for more than 90 days.
  3. Kidney retransplantation.
  4. Sustained eGFR ≤15 mL/min/1.73 m² for more than 3 months.
  5. Sustained 40% decline in eGFR from screening, confirmed by two serum creatinine measurements obtained at least 3 months apart.
  6. Total eGFR slope, calculated using longitudinal eGFR measurements from screening to the end of study drug treatment and expressed in mL/min/1.73 m²/year.

The components will be evaluated according to their prespecified hierarchical ranking.

From randomization to the end of the study (up to 4.5 years); eGFR slope assessed from screening to the end of study drug treatment.
Hierarchical Composite of Cardiovascular Death, Non-Fatal Stroke, Non-Fatal Myocardial Infarction, and Heart Failure Events
Tidsramme: From randomization to the end of the study (up to 4.5 years).

A hierarchical composite cardiovascular endpoint consisting of the following components:

  1. Cardiovascular death.
  2. Non-fatal stroke.
  3. Non-fatal myocardial infarction.
  4. Heart failure events, defined as hospitalization for heart failure or urgent treatment for heart failure.

The components will be evaluated according to their prespecified hierarchical ranking.

From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Cardiovascular Death
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants who die due to cardiovascular causes during the study period.

From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Kidney Death
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants who die due to kidney-related causes during the study period.

From randomization to the end of the study (up to 4.5 years).
Total eGFR Slope from Screening to the End of Study Drug Treatment
Tidsramme: From screening to the end of study drug treatment (up to 4.5 years).

The total eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements from screening to the end of study drug treatment.

From screening to the end of study drug treatment (up to 4.5 years).
Chronic eGFR Slope from 3 Months Post-Randomization to the End of Study Drug Treatment
Tidsramme: From 3 months post-randomization to the end of study drug treatment (up to 4.5 years).

The chronic eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements beginning 3 months after randomization and continuing to the end of study drug treatment.

From 3 months post-randomization to the end of study drug treatment (up to 4.5 years).
Comprehensive eGFR Slope from Screening to the End of the Study Washout Period
Tidsramme: From screening to the end of the study washout period (up to 4.5 years).

The comprehensive eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements from screening through the end of the study washout period.

From screening to the end of the study washout period (up to 4.5 years).

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants Developing New-Onset Diabetes
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants without diabetes at baseline who develop new-onset diabetes during the study period.

From randomization to the end of the study (up to 4.5 years).
Change from Baseline in Body Weight Over the Study Drug Treatment Period
Tidsramme: Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).

Change in body weight, measured in kilograms, from baseline (pre-randomization) to the end of study drug treatment. Body weight will be measured at the scheduled study visits to assess changes over time.

Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).
Number of Participants Permanently Discontinuing Study Drug
Tidsramme: From randomization to the end of study drug treatment (up to 4.5 years).

Number of participants who permanently discontinue their assigned study drug before the planned end of study drug treatment.

From randomization to the end of study drug treatment (up to 4.5 years).
Change from Baseline in Urine Albumin-to-Creatinine Ratio Over the Study Drug Treatment Period
Tidsramme: Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).

Change in urine albumin-to-creatinine ratio (UACR) from baseline (pre-randomization) to the end of study drug treatment. UACR will be measured using urine albumin and creatinine concentrations and expressed in mg/g (or the units specified by the laboratory). Measurements at scheduled study visits will be used to assess the trajectory of UACR over time.

Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).
Number of Participants Experiencing Acute Kidney Injury
Tidsramme: From randomization to the end of the study (up to 4.5 years).

Number of participants experiencing at least one episode of acute kidney injury during the study period, according to the prespecified diagnostic criteria.

From randomization to the end of the study (up to 4.5 years).

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Vikas S Sridhar, MD PhD, University of British Columbia
  • Hovedetterforsker: David ZI Cherney, MD PhD, University Health Network, Toronto
  • Hovedetterforsker: Steve Chadban, BMed(hons) PhD, Royal Prince Alfred Hospital, Sydney, Australia
  • Hovedetterforsker: John Gill, MD MS, University of British Columbia
  • Hovedetterforsker: Arthur Matas, MD, University of Minnesota (Minneapolis)
  • Hovedetterforsker: Amy Mottl, MD MPH FASN, University of North Carolina, Chapel Hill
  • Hovedetterforsker: Deirdre Sawinski, MD, Weill Medical College of Cornell University
  • Hovedetterforsker: Sunita KS Singh, MD MSc, University Health Network, Toronto
  • Hovedetterforsker: David Vock, PhD, University of Minnesota (Minneapolis)
  • Hovedetterforsker: Erika Helgeson, PhD, University of Minnesota (Minneapolis)

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. april 2027

Primær fullføring (Antatt)

1. oktober 2031

Studiet fullført (Antatt)

1. mars 2032

Datoer for studieregistrering

Først innsendt

7. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere